I am pleased to inform you that the company H4 Orphan Pharma met with the Belgian drug agency on September 12 in Brussels. The agency authorizes us to go directly into clinical phase 2 for idiopathic pulmonary fibrosis. This is excellent news for our company, but also for all H4O employees and associates who contributed to this success.